Vertex Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Vertex Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Vertex Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Vertex Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreVertex Pharmaceuticals Inc (Vertex) is a biotechnology company that discovers, develops, and manufactures transformative medicines for serious diseases. Vertex's major products include therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company's products are distributed through local and international pharmacies, hospitals, clinics, specialty distributors to patients, health care providers, and authorized treatment centers. Vertex offers its products in the Americas, Europe, Asia, and the Middle East, through the brands Alyftrek, Casgevy, Kaftrio, Orkambi, and Trikafta, among others. It operates manufacturing facilities in the US and collaborates to manufacture its products. Vertex is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
50 Northern Avenue, Boston, Massachusetts, 02210
Website
www.vrtx.com
Telephone
1 617 3416100
No of Employees
6,400
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VRTX (NASD)
Revenue (2024)
$12.0B
8.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
838.1%
(2024 vs 2023)
Market Cap*
$126.4B
Net Profit Margin (2024)
XYZ
777.8%
(2024 vs 2023)
* As of and is in US$
Vertex Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Medicine for Cystic Fibrosis | Vertex |
| Medicine for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | Kalydeco |
| Medicine for Acute Pain | Orkambi |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company signed an agreement with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY (exagamglogene autotemcel). |
| 2026 | Regulation/Government Policy | In April, the company announced the US FDA approval for label extensions of Alyftrek and Trikafta. |
| 2025 | Contracts/Agreements | In September, the company signed a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia and severe sickle cell disease (SCD) patients. |
Competitor Comparison
| Key Parameters | Vertex Pharmaceuticals Inc | Eli Lilly and Co | Merck & Co Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Boston | Indianapolis | Rahway | North Chicago | Cambridge |
| State/Province | Massachusetts | Indiana | New Jersey | Illinois | Cambridgeshire |
| No. of Employees | 6,400 | 50,605 | 75,000 | 57,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeffrey M. Leiden, MD, PhD | Chairman | Executive Board | 2020 | 70 |
| Reshma Kewalramani, MD | Chief Executive Officer; Director; President | Executive Board | 2020 | 53 |
| Charles F. Wagner, Jr. | Chief Financial Officer; Chief Operating Officer; Executive Vice President | Senior Management | 2025 | 57 |
| Joy Liu | Executive Vice President; Chief Legal Officer | Senior Management | 2026 | - |
| Carmen Bozic, MD | Chief Medical Officer; Executive Vice President - Global Medicines Development and Medical Affairs | Senior Management | 2020 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer